A variant of the interleukin  7 gene is associated with an increased risk of immune-related adverse events in people with cancer receiving immune checkpoint inhibitor therapy, suggests research.

Normalized expression levels of the DNA repair protein MRE11 could help to identify patients with nonmetastatic muscle-invasive bladder cancer likely to benefit from bladder-preserving trimodality therapy, suggests research.

Osimertinib elicits high rates of systemic and intracranial response in people with advanced non-small-cell lung cancer harboring uncommon EGFR mutations, say the authors of the real-world UNICORN study.

Find out more about these consensus guidelines here

A retrospective analysis points to the utility of intra-tumor copy number heterogeneity to identify patients with node-negative, estrogen receptor-positive breast cancer who may be able to forgo adjuvant endocrine therapy.

A large US study has shown the feasibility of circulating tumor DNA analysis to detect KRAS G12C mutations in patients with solid tumors.

The sensitivity of the selective tyrosine kinase inhibitor poziotinib in people with advanced non-small-cell lung cancer and EGFR exon 20 insertions is “highly dependent” on the location of the insertion, US researchers have found.

Researchers have used computer-based analyses to identify and confirm a large number genetic biomarkers that predict cancer treatment outcomes, as well as gene–gene interactions that may modify the effects of targeted treatments.

Adding capivasertib to fulvestrant significantly improves survival in patients with aromatase inhibitor resistant, estrogen receptor-positive, HER2-negative advanced breast cancer, particularly those with PIK3CA / AKT1 / PTEN alterations, FAKTION data show.

The use of adjuvant chemotherapy in patients with hormone receptor-positive, HER2-negative early breast cancer and up to three positive lymph nodes could be guided by the 21-gene recurrence score and response to preoperative endocrine therapy, research suggests.

Individuals with non-small-cell lung cancer harboring uncommon or very rare EGFR mutations benefit from treatment with EGFR–tyrosine kinase inhibitors, but those with exon 20 insertions do not, German research suggests.

Men with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations could benefit from the addition of niraparib to first-line abiraterone acetate plus prednisone, suggest phase 3 trial data.

Individuals with 70-gene signature ultralow-risk breast cancers are significantly less likely to experience distant metastasis or breast cancer-related death than those with low-risk tumors, show data from the phase 3 MINDACT trial.

People with Li-Fraumeni syndrome, who carry pathogenic or likely pathogenic germline TP53 variants, are 24 times more likely to develop cancer than people from the general population, research shows.

Germline pathogenic variants in five hereditary cancer genes, including BRCA2 , are significantly associated with invasive lobular carcinoma risk, US study findings indicate.

A survey of US oncologists and physicians has shown that their perceived barriers toward genetic counseling and testing for breast cancer vary by patients' race.

Men who carry germline mismatch repair pathogenic variants in the MSH2 and MSH6 genes, typically associated with Lynch syndrome, have a significantly higher incidence of prostate cancer than noncarriers, show early data from the IMPACT study.

PARP1 could help identify patients with advanced clear cell renal cell carcinoma who are likely to benefit from immune checkpoint inhibitor treatment, with particular utility in those with PBRM1 -mutated disease, indicate findings.